In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Alina Iovleva; Christi L. McElheny; Erin L. Fowler; Eric Cober; Erica S. Herc; Cesar A. Arias; Carol Hill; Keri Baum; Vance G. Fowler; Henry F. Chambers; Kerryl E. Greenwood-Quaintance; Robin Patel; David van Duin; Robert A. Bonomo; Yohei Doi

doi:10.1128/aac.01258-23

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Alina Iovleva
, Christi L. McElheny
, Erin L. Fowler
, Eric Cober
, Erica S. Herc
, Cesar A. Arias
, Carol Hill
, Keri Baum
, Vance G. Fowler
, Henry F. Chambers
, Kerryl E. Greenwood-Quaintance
, Robin Patel
, David van Duin
, Robert A. Bonomo
, Yohei Doi

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC₅₀/MIC₉₀ values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.

Original language	English
Journal	Antimicrobial agents and chemotherapy
Volume	68
Issue number	3
DOIs	https://doi.org/10.1128/aac.01258-23
Publication status	Published - 03-2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/aac.01258-23

Cite this

Iovleva, A., McElheny, C. L., Fowler, E. L., Cober, E., Herc, E. S., Arias, C. A., Hill, C., Baum, K., Fowler, V. G., Chambers, H. F., Greenwood-Quaintance, K. E., Patel, R., van Duin, D., Bonomo, R. A., & Doi, Y. (2024). In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrobial agents and chemotherapy, 68(3). https://doi.org/10.1128/aac.01258-23

@article{c390c442bd7f4e34b86ddff795070a21,

title = "In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals",

abstract = "The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89\% and 97\% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.",

keywords = "antimicrobial resistance, diazabicyclooctane, surveillance",

author = "Alina Iovleva and McElheny, \{Christi L.\} and Fowler, \{Erin L.\} and Eric Cober and Herc, \{Erica S.\} and Arias, \{Cesar A.\} and Carol Hill and Keri Baum and Fowler, \{Vance G.\} and Chambers, \{Henry F.\} and Greenwood-Quaintance, \{Kerryl E.\} and Robin Patel and \{van Duin\}, David and Bonomo, \{Robert A.\} and Yohei Doi",

year = "2024",

month = mar,

doi = "10.1128/aac.01258-23",

language = "English",

volume = "68",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

Iovleva, A, McElheny, CL, Fowler, EL, Cober, E, Herc, ES, Arias, CA, Hill, C, Baum, K, Fowler, VG, Chambers, HF, Greenwood-Quaintance, KE, Patel, R, van Duin, D, Bonomo, RA & Doi, Y 2024, 'In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals', Antimicrobial agents and chemotherapy, vol. 68, no. 3. https://doi.org/10.1128/aac.01258-23

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. / Iovleva, Alina; McElheny, Christi L.; Fowler, Erin L. et al.
In: Antimicrobial agents and chemotherapy, Vol. 68, No. 3, 03.2024.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

AU - Iovleva, Alina

AU - McElheny, Christi L.

AU - Fowler, Erin L.

AU - Cober, Eric

AU - Herc, Erica S.

AU - Arias, Cesar A.

AU - Hill, Carol

AU - Baum, Keri

AU - Fowler, Vance G.

AU - Chambers, Henry F.

AU - Greenwood-Quaintance, Kerryl E.

AU - Patel, Robin

AU - van Duin, David

AU - Bonomo, Robert A.

AU - Doi, Yohei

PY - 2024/3

Y1 - 2024/3

N2 - The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.

AB - The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.

KW - antimicrobial resistance

KW - diazabicyclooctane

KW - surveillance

UR - https://www.scopus.com/pages/publications/85187106929

UR - https://www.scopus.com/pages/publications/85187106929#tab=citedBy

U2 - 10.1128/aac.01258-23

DO - 10.1128/aac.01258-23

M3 - Article

C2 - 38289078

AN - SCOPUS:85187106929

SN - 0066-4804

VL - 68

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 3

ER -

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this